(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 5.78% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Myriad Genetics's revenue in 2026 is $824,500,000.On average, 15 Wall Street analysts forecast MYGN's revenue for 2026 to be $82,405,940,570, with the lowest MYGN revenue forecast at $76,920,751,611, and the highest MYGN revenue forecast at $85,478,618,871. On average, 15 Wall Street analysts forecast MYGN's revenue for 2027 to be $86,813,915,468, with the lowest MYGN revenue forecast at $78,737,615,257, and the highest MYGN revenue forecast at $92,597,395,473.
In 2028, MYGN is forecast to generate $91,259,293,632 in revenue, with the lowest revenue forecast at $80,691,935,905 and the highest revenue forecast at $100,334,261,045.